Breaking News

Grand River Completes Fourth FDA Inspection

February 10, 2016

Found to be in compliance with cGMPs, passes Pre-Approval Inspection

Grand River Aseptic Manufacturing, Inc. (GRAM) has successfully completed its fourth FDA inspection at its contract parenteral manufacturing facility in Grand Rapids, MI.
 
The seven-day inspection included a general GMP and a Pre-Approval Inspection, which found GRAM to be in compliance with Current Good Manufacturing Practices. GRAM also passed the Pre-Approval Inspection, with no Form 483 observations issued. 
 
Tom Ross, president and chief executive officer at GRAM said, “GRAM team members proved that dedication to superior regulatory and quality performance is the only way to operate. We are thrilled to deliver this news to our clients and I congratulate the entire GRAM team on a job well done.  Each year, our top five strategic objectives start with superior regulatory performance. Our company focus will always be on quality, and receiving zero 483s is a fantastic achievement.”

Related Compliance:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision